Drug Profile
Research programme: drug discovery - Reliance Life Sciences
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Reliance Life Sciences
- Class Monoclonal antibodies; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Eye disorders; Infections; Inflammation; Neurodegenerative disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in India (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Eye-disorders in India (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Infections in India (Parenteral)